特发性矮小症和生长激素缺乏症应用重组人生长激素的效果对比  

Clinical Efficacy of Recombinant Human Growth Hormone in Treatment of Idiopathic Short Stature and Growth Hormone Deficiency

作　　者：魏苗苗[1] WEI Miaomiao(The First People’s Hospital of Huizhou City,Huizhou 516000,China)

机构地区：[1]广东省惠州市第一人民医院,广东惠州516000

出　　处：《中国医学创新》2019年第1期142-145,共4页Medical Innovation of China

摘　　要：目的:探究特发性矮小症(ISS)和生长激素缺乏症(GHD)应用重组人生长激素(rhGH)治疗的临床疗效。方法:选取2014年5月-2016年10月本院收治的ISS和GHD患者各30例,分别作为ISS组和GHD组。两组患者均于睡前30 min予以皮下注射相同剂量的rhGH,治疗时间为12个月。比较两组治疗前后的生长发育指标(身高、体质指数、生长速率和骨龄)、生化指标(FPG、IGF-1、IGFBP-3)和不良反应发生率。结果:治疗后,两组身高、生长速率、骨龄、IGF-1和IGFBP-3均高于治疗前,且GHD组均高于ISS组,比较差异均有统计学意义(P<0.05),但治疗后两组体质指数、FPG比较,差异均无统计学意义(P>0.05);GHD组不良反应发生率为6.67%,低于ISS组的26.67%(P<0.05)。结论:与ISS相比,GHD患者应用rhGH治疗后生长发育恢复更明显,并发症发生率更低,安全性较好。Objective:To observe the clinical efficacy of Recombinant Human Growth Hormone(rhGH)in treatment of idiopathic short stature(ISS)and growth hormone deficiency(GHD).Method:A total of 30 children with ISS and GHD treated in our hospital from May 2014 to October 2016 were selected as ISS group and GHD group respectively.Both groups were subcutaneously injected with the same dose of rhGH 30 minutes before bedtime for 12 months.The growth and development indicators(height,body mass index,growth rate and bone age)and biochemical indicators(FPG,IGF-1,IGFBP-3)before and after treatment,and incidence of adverse reactions between two groups were compared.Result:After treatment,the height,growth rate,bone age,IGF-1 and IGFBP-3 of two groups were higher than those of before treatment,and GHD group were higher than those of ISS group,the differences were statistically significant(P<0.05).But after treatment,the body mass index and FPG of two groups were compared,the differences were not statistically significant(P>0.05).The incidence of adverse reactions in GHD group was 6.67%lower than 26.67%in ISS group(P<0.05).Conclusion:Compared with ISS,the growth and development recovery of GHD patients after rhGH treatment is more obvious,the incidence of complications is lower,and the safety is better.

关 键 词：重组人生长激素 特发性矮小症 生长激素缺乏症 儿童 

分 类 号：R725.8[医药卫生—儿科]